Literature DB >> 6737012

Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis.

A Leonardi, G Abbruzzese, L Arata, L Cocito, M Vische.   

Abstract

The cerebrospinal fluid (CSF) was examined in 90 amyotrophic lateral sclerosis (ALS) patients and in 50 age-matched normal controls. Total protein concentration was significantly higher in ALS patients than in normal controls. CSF IgG and albumin, quantitatively determined by single radial immunodiffusion, were significantly increased in ALS. No difference in serum concentrations was observed between ALS patients and normal controls. On isoelectric focusing a clearcut "fingerprint" pattern was observed in 11 of 12 cases. These findings support the hypothesis that blood-brain barrier damage occurs in ALS. The finding of a higher mononuclear cell count in young ALS patients is briefly discussed in the light of the hypothesis that an exogenous agent might be of some relevance in pathogenesis. An alteration of at least one of the CSF parameters considered was found in 45.5% of ALS cases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6737012     DOI: 10.1007/BF00313720

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Viruslike particles in amyotrophic lateral sclerosis: electron microscopical study of a case.

Authors:  C E Peña
Journal:  Ann Neurol       Date:  1977-03       Impact factor: 10.422

2.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

3.  Isoelectric focusing of CSF proteins in neurological diseases.

Authors:  K G Kjellin; O Vesterberg
Journal:  J Neurol Sci       Date:  1974-10       Impact factor: 3.181

4.  Diagnostic significance of cereborspinal-fluid examinations in myelopathy.

Authors:  A Gårde; K G Kjellin
Journal:  Acta Neurol Scand       Date:  1971       Impact factor: 3.209

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid.

Authors:  H Reiber
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

7.  Motor neurone disease with elevated cerebrospinal fluid protein.

Authors:  R J Guiloff; B McGregor; E Thompson; W Blackwood; E Paul
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-05       Impact factor: 10.154

8.  Isoelectric focusing and electrophoresis of cerebrospinal fluid proteins in muscular dystrophies and spinal muscular atrophies.

Authors:  K G Kjellin; H Stibler
Journal:  J Neurol Sci       Date:  1976-01       Impact factor: 3.181

9.  Amyotrophic lateral sclerosis. Clinical features and prognosis.

Authors:  A D Rosen
Journal:  Arch Neurol       Date:  1978-10

10.  [Amyotrophic lateral sclerosis occuring befor the age of 40 years. Remarks apropos of 25 cases].

Authors:  G Aimard; B Bady; D Boisson; P Trouillas; M Devic
Journal:  Rev Neurol (Paris)       Date:  1976-08       Impact factor: 2.607

View more
  23 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

2.  Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.

Authors:  Sebastian A Lewandowski; Ingrid Nilsson; Linda Fredriksson; Peter Lönnerberg; Lars Muhl; Manuel Zeitelhofer; Milena Z Adzemovic; Susanne Nichterwitz; Daniel A Lawrence; Eva Hedlund; Ulf Eriksson
Journal:  Acta Neuropathol       Date:  2015-12-19       Impact factor: 17.088

3.  Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

Authors:  Sarah Jesse; Johannes Brettschneider; Sigurd D Süssmuth; Bernhard G Landwehrmeyer; Christine A F von Arnim; Albert C Ludolph; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2010-12-25       Impact factor: 4.849

4.  Hypercapnia is a possible determinant of the function of the blood-cerebrospinal fluid barrier in amyotrophic lateral sclerosis.

Authors:  Sigurd D Süssmuth; Anne D Sperfeld; Albert C Ludolph; Hayrettin Tumani
Journal:  Neurochem Res       Date:  2010-03-24       Impact factor: 3.996

Review 5.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

Review 6.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

Review 7.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

Review 8.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

Review 9.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

10.  The APCs of neuroprotection.

Authors:  Charles T Esmon; Jonathan D Glass
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.